Company intelligence / Profile preview

EnzymenRx

Ownership: Private
Development stage: Other

Overview

EnzymenRx is a biotechnology company focused on developing innovative enzyme replacement therapies for rare metabolic disorders. The company's lead program targets Phenylketonuria (PKU) by utilizing a proprietary recombinant enzyme designed to restore the body's ability to metabolize phenylalanine. EnzymenRx aims to improve patient outcomes through more stable and effective enzymatic treatments compared to current standards of care. The company is currently in the pre-clinical stage, advancing its lead candidate toward IND-enabling studies.

Therapeutic areas: Metabolic Disorders
Modalities: Enzyme replacement therapyRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on EnzymenRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EnzymenRx.

Explore the full profile